Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Abeona Therapeutics Q3 2026 Results: Net Loss of $4.81M, Loss Narrows

Abeona Therapeutics reported a decrease in cash and short-term investments to $134.9 million as of September 30, 2026, compared to $191.4 million at year-end 2025. The company is focused on the commercialization of ZEVASKYN and the development of ABO-801, while noting a private placement transaction announced on November 9, 2026.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue13.5—
Profit before tax-4.8-20.4
Net income-4.8-5.2
EPS (diluted, $ a share)$-0.08$-0.10

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Operating margin-96.4%
Source

10-Q filed with the SEC, NASDAQ: ABEO. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Abeona Therapeutics Inc.: key numbers

Share price
$2.60Close, Nov 17
Market cap
$149M
Shares outstanding
57.15MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Abeona Therapeutics Inc.

All →
8:02 AM ET Form 4
Insider Buying

Abeona Therapeutics Insider Faith L. Charles Buys $34.3K of Stock

Faith L. Charles bought 15,000 shares of Abeona Therapeutics Inc. at $2.29 a share, worth $34.3K in total on Nov 13, 2026. Shares held after the trade: 191,407 (+8.5%).

Value
$34.3K
Shares
15,000
Price
$2.29
Holding change
+8.5%
Trade date
Nov 13, 2026
6:36 AM ET 8-K
Financial Results

Abeona Therapeutics Financial Results

Abeona Therapeutics reported Q3 2026 financial results, highlighted by $13.5 million in net ZEVASKYN revenue, an 18% sequential increase. The company completed six ZEVASKYN treatments during the quarter and expanded its qualified treatment center network to eight sites. Additionally, Abeona announced the acquisition of a Phase 3-ready asset, APT-1011, for eosinophilic esophagitis and a $30 million PIPE financing.

Term
Q3 2026

“Maximizing the opportunity for ZEVASKYN remains our number one priority. During the third quarter, we continued to build the commercial foundation for ZEVASKYN, with expansion of our QTC network and more centers gaining firsthand treatment experience.”

Vish Seshadri, Ph.D., Chief Executive Officer of Abeona Therapeutics

“The acquisition of APT-1011 represents an important step in building Abeona into a diversified commercial-stage company, adding a uniquely differentiated late-stage orphan-drug asset with substantial commercial potential in a rapidly growing disease with high unmet need.”

Vish Seshadri, Ph.D., Chief Executive Officer of Abeona Therapeutics
6:31 AM ET 8-K
M&A Deal

Abeona Therapeutics Signs $20M M&A Deal with Ellodi Pharmaceuticals, L.P.

Abeona Therapeutics acquired substantially all assets related to APT-1011 (now ABO-801), a Phase 3-ready candidate for eosinophilic esophagitis, from Ellodi Pharmaceuticals. The deal was structured with $20 million in upfront equity consideration (4,494,383 shares) and no upfront cash, with Ellodi eligible for $30 million upon FDA approval and up to $30 million in sales milestones plus royalties.

Value
$20M
Counterparty
Ellodi Pharmaceuticals, L.P.

“The acquisition of ABO-801 is an important step in building Abeona into a diversified commercial-stage company with multiple opportunities for value inflection, adding an asset with substantial revenue potential in a rapidly growing disease.”

Vish Seshadri, Ph.D., Chief Executive Officer of Abeona Therapeutics
2:20 AM ET Form 4
Insider Selling

Abeona Therapeutics Chief Commercial Officer Madhav Vasanthavada Sells $25.3K of Stock

Madhav Vasanthavada, Chief Commercial Officer, sold 4,902 shares of Abeona Therapeutics Inc. at $5.16 a share, worth $25.3K in total on Sep 29, 2026. Shares held after the trade: 285,721 (-1.7%).

Value
$25.3K
Shares
4,902
Price
$5.16
Role
Chief Commercial Officer
Holding change
-1.7%
Trade date
Sep 29, 2026
2:20 AM ET Form 4
Insider Selling

Abeona Therapeutics SVP, CLO Brendan M. O'Malley Sells $34.7K of Stock

Brendan M. O'Malley, SVP, CLO, sold 6,727 shares of Abeona Therapeutics Inc. at $5.16 a share, worth $34.7K in total on Sep 29, 2026. Shares held after the trade: 421,226 (-1.6%).

Value
$34.7K
Shares
6,727
Price
$5.16
Role
SVP, CLO
Holding change
-1.6%
Trade date
Sep 29, 2026
2:20 AM ET Form 4
Insider Selling

Abeona Therapeutics CFO Joseph Walter Vazzano Sells $47.4K of Stock

Joseph Walter Vazzano, CFO, sold 9,191 shares of Abeona Therapeutics Inc. at $5.16 a share, worth $47.4K in total on Sep 29, 2026. Shares held after the trade: 482,888 (-1.9%).

Value
$47.4K
Shares
9,191
Price
$5.16
Role
CFO
Holding change
-1.9%
Trade date
Sep 29, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.